Form 4: Cytosorbents Corp Executive Exercises Subscription Rights, Acquires Shares and Warrants

Cytosorbents Corp's President and COO, Vincent Capponi, exercised subscription rights to acquire shares and warrants as part of a recent rights offering.

Summary

• Vincent Capponi, President and COO of Cytosorbents Corp, exercised subscription rights on January 17, 2025, acquiring 31,760 shares of common stock, Series A warrants, and Series B warrants.
• The subscription rights were part of a rights offering where each unit, consisting of one share, one Series A warrant, and one Series B warrant, was priced at $1.00.
• The total cost for the 31,760 units was $31,760.
• The Series A warrants have an exercise price that is 90% of the 5-day volume weighted average price of the company's common stock prior to their expiration, with a floor of $1.00 and a ceiling of $2.00.
• The Series B warrants have an exercise price that is 90% of the 5-day volume weighted average price of the company's common stock prior to their expiration, with a floor of $2.00 and a ceiling of $4.00.
• The Series A warrants expire 45 days after the closing date of the rights offering, and the Series B warrants expire 90 days after the closing date.

Sentiment

Score: 7

Explanation: The document reflects a positive sentiment due to the executive's participation in the rights offering, indicating confidence in the company. However, it is a routine transaction and not a major catalyst.

Positives

• The exercise of subscription rights by a key executive demonstrates confidence in the company's future prospects.
• The acquisition of shares and warrants by the President and COO aligns his interests with those of the shareholders.

Risks

• The value of the warrants is dependent on the future performance of the company's stock price.
• The exercise price of the warrants is variable and could be higher than the current stock price.

Industry Context

This transaction is a standard part of executive compensation and capital raising activities in the biotechnology industry.

Comparison to Industry Standards

• The use of subscription rights and warrants is a common practice in the biotech industry to raise capital and incentivize executives.
• Many biotech companies use similar structures for rights offerings, often with warrants attached to the shares.
• The exercise price ranges for the warrants are typical for this type of offering, designed to provide upside potential while protecting against significant downside risk.

Stakeholder Impact

• The transaction is likely to have a neutral to slightly positive impact on shareholders, as it demonstrates executive confidence.
• The exercise of warrants could lead to future dilution of shares if the warrants are exercised.

Key Dates

Keywords

Cytosorbents Corp, Subscription Rights, Vincent Capponi, Warrants, Common Stock, Executive Transaction, Rights Offering